UBS Group’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.05M | Buy |
|
|||||
|
2025
Q2 | $411K | Buy |
|
|||||
|
2025
Q1 | $543K | Buy |
|
|||||
|
2024
Q4 | $470K | Buy |
|
|||||
|
2024
Q3 | $143K | Sell |
|
|||||
|
2024
Q2 | $159K | Sell |
|
|||||
|
2024
Q1 | $158K | Sell |
|
|||||
|
2023
Q4 | $186K | Sell |
|
|||||
|
2023
Q3 | $498K | Sell |
|
|||||
|
2023
Q2 | $749K | Buy |
|
|||||
|
2023
Q1 | $63.6K | Buy |
|
|||||
|
2022
Q4 | $12.5K | Sell |
|
|||||
|
2022
Q3 | $138K | Sell |
|
|||||
|
2022
Q2 | $3.04M | Sell |
|
|||||
|
2022
Q1 | $4.27M | Buy |
|
|||||
|
2021
Q4 | $735K | Buy |
|
|||||
|
2021
Q3 | $1.21M | Buy |
|
|||||
|
2021
Q2 | $168K | Sell |
|
|||||
|
2021
Q1 | $581K | Sell |
|
|||||
|
2020
Q4 | $702K | Sell |
|
|||||
|
2020
Q3 | $785K | Buy |
|
|||||
|
2020
Q2 | $14K | Sell |
|
|||||
|
2020
Q1 | $37K | Sell |
|
|||||
|
2019
Q4 | $242K | Buy |
|
|||||
|
2019
Q3 | $132K | Buy |
|
|||||
|
2019
Q2 | $56K | Sell |
|
|||||
|
2019
Q1 | $116K | Buy |
|
|||||
|
2018
Q4 | $106K | Buy |
|
|||||
|
2018
Q3 | $155K | Buy |
|
|||||
|
2018
Q2 | $57K | Buy |
|
|||||
|
2018
Q1 | $48K | Buy |
|
|||||
|
2017
Q4 | $13K | Buy |
|
|||||
|
2017
Q3 | $9K | Buy |
|
|||||
|
2017
Q2 | $5K | Sell |
|
|||||
|
2017
Q1 | $9K | Buy |
|
|||||
|
2016
Q2 | – | Sell |
|
|||||
|
2016
Q1 | $12K | Buy |
|
|||||
|
2015
Q4 | $0 | Sell |
|
|||||
|
2015
Q3 | $9K | Sell |
|
|||||
|
2015
Q2 | $15K | Buy |
|
|||||
|
2015
Q1 | $2K | Buy |
|